Click Here to return To Results

 

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica NEJM 388:511-517, Kin,B.S.,et al, 2023 See this aricle in Pubmed Article Abstract Among patients with notalgia paresthetica, oral treatment with difelikefalin resulted in modestly greater reductions in itch intensity scores than placebo over a period of 8 weeks but was associated with adverse events.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction burning paresthesia difelikefalin mononeuropathy mononeuropathy,sensory notalgia paresthetica pruritus treatment of neurologic disorder

Click Here to return To Results